Natera Inc

Natera Inc., established in 2004, is a pioneering entity specialized in genetic testing and analysis. Headquartered in San Carlos, California, United States, it has carved out a significant niche in women's health, oncology, and organ health with its cutting-edge products and services. Within the women's health segment, Natera Inc. brings forth tests like Panorama, a non-invasive prenatal test that detects common fetal chromosomal anomalies, as well as Horizon, which screens for potential genetic conditions that future parents might carry. Both play crucial roles for expectant parents seeking early and informative insights. The company's foray into oncology is marked by its proprietary Signatera test, which is a personalized circulating tumor DNA test. This innovation serves as an invaluable tool in the monitoring and molecular residual disease assessment in cancer patients, tailoring treatments to the unique genetic profile of an individual's cancer. In the realm of organ health, Natera Inc. offers Prospera, a sophisticated test that identifies signs of kidney transplant rejection from a simple blood sample, thereby circumventing the need for invasive biopsy procedures. While the United States remains the primary market for Natera Inc., the company's global footprint is expanding. Its products and services are available in various countries around the world, supported by strategic distribution partnerships and networks, making Natera Inc. a global contender in the genetic testing landscape. (Powered by AI)